Get Plus

Sign in to baba News

One account across the web, iPhone and Android — your subscription follows it.

or use an email code

Search stories

Type at least two characters. Results come from every newsroom baba reads.

↑↓ to move · ↵ to open · esc to close

Sign in to baba News

Sign in to keep asking. News Plus removes the daily limit.

or use an email code

developing· Health· Updated

Obesity Drug Shows Promising Results for Children Aged 6-11

A new international study published in the New England Journal of Medicine has found that the weight-loss drug Wegovy, manufactured by Novo Nordisk, is highly effective in treating severe obesity in children aged 6 to 11. The trial involved 165 children, according to Kan News and Arutz Sheva, or 167 children according to Ynet, who received weekly injections of semaglutide alongside nutritional and exercise guidance.

3 newsrooms · 1 language · since

Sign in to baba News

Sign in to save this article and find it on your phone.

or use an email code

Obesity Drug Shows Promising Results for Children Aged 6-11
Illustration by baba

What happened

  1. 01A new study published in the New England Journal of Medicine shows Wegovy is highly effective for severely obese children aged 6 to 11.
  2. 02After 68 weeks of treatment, approximately 40% of the children receiving Wegovy no longer met the medical definition of obesity.
  3. 03Children treated with Wegovy experienced an average BMI reduction of 17.4%, compared to a 2.2% increase in the placebo group.
  4. 04Three Israeli medical centers, Schneider, Shamir, and Rambam, participated in the international trial, which included 16 Israeli children.
  5. 05Wegovy is already included in Israel's national health basket for adolescents aged 12 to 18 who meet specific criteria.
  6. 06Novo Nordisk reported no negative impacts on children's growth, with side effects like nausea and diarrhea similar to those in adults.
  7. 07Novo Nordisk plans to seek FDA approval to expand the approved use of Wegovy to children aged 6 to 11.

Over the 68-week study, children treated with Wegovy experienced an average body mass index (BMI) reduction of 17.4%, while those in the placebo group saw a 2.2% increase. Approximately 40% of the children who received the drug no longer met the medical definition of obesity by the end of the trial, a result that was not observed in any children in the placebo group. Additionally, nearly 80% of the treated children achieved at least a 10% decrease in BMI, according to Ynet.

Three Israeli medical centers, Schneider, Shamir, and Rambam, participated in the research, which included 16 children from Israel. Wegovy is already available in Israel's national health basket for adolescents aged 12 to 18 who meet specific medical criteria. Novo Nordisk reported no adverse effects on the children's growth or development, with side effects being similar to those seen in adults and adolescents, primarily nausea, diarrhea, vomiting, abdominal pain, gas, heartburn, and hair loss. Following these results, Novo Nordisk plans to seek FDA approval to expand the drug's use to this younger age group.

Summarized by baba from the reports of 3 newsrooms. Updated

Latest report: Arutz Sheva. Read Arutz Sheva’s original

The coverage

3 newsrooms on this story

Who covered it

  • LeftNone
  • Centre2
  • Right1
  • HarediNone
  • ArabNone

How it broke

See which of the 3 newsrooms broke it, and who waited